Conditions that can be fatal due to uncontrolled secretion of mucus in the airways such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF), as well as cancer and lung disease, and its treatment, can now be treated using drugs developed by scientists at the University of Texas MD Anderson Cancer Center, as published in the journal Nature.
“Mucus is an important issue in pulmonary medicine, because in people with these common lung diseases, thick mucus can block the airways and cause symptoms ranging from a mild cough to a very severe decrease in function.” lung capacity Most medicines for these conditions work to reduce inflammation or widen the airways to help people breathe better, but mucus is the most serious problem. developed the first drug that can block the secretion of mucus in the airways” Burton Dickey, MD, professor of Pulmonary Medicine and co-author of the study.
Scientists have developed the first drug to treat potentially life-threatening respiratory conditions such as asthma, COPD, cystic fibrosis and cancer-related lung disease. ‘
In the US, about 25 million people have asthma, 16 million adults are diagnosed with COPD, and CF is the most common genetic, life-threatening disease.
The team discovered that the drug named SP9 pinning peptide is beneficial in blocking a specific protein (synaptotagmin-2 (Syt2)) which is the best protein to target to block mucin secretion.
Further validation of the data could help shape typical therapies against lung diseases.